Cognition Therapeutics (CGTX) Depreciation & Amortization (CF) (2020 - 2025)
Cognition Therapeutics (CGTX) posted quarterly Depreciation & Amortization (CF) of $14000.0 for Q4 2025, down 48.15% year-over-year from $27000.0 in Q4 2024, and down 6.67% quarter-over-quarter from $15000.0 in Q3 2025.
Cognition Therapeutics (CGTX) Depreciation & Amortization (CF) (2020 - 2025) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $14000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) fell 48.15% year-over-year to $14000.0; the TTM figure through Mar 2026 stood at $29000.0 (down 63.75% YoY), while the FY2025 annual figure was $36000.0, down 66.36% from the prior year.
- Depreciation & Amortization (CF) eased to $14000.0 in Q4 2025 per CGTX's latest filing, from $15000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $27000.0 in Q4 2023 and bottomed at $14000.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $22666.7 across 5 years, with a median of $23000.0 in 2021.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) climbed 28.57% — and 2025, when it plunged 48.15%.
- Cognition Therapeutics' Depreciation & Amortization (CF) stood at $23000.0 in 2021, then changed by 0.0% to $23000.0 in 2022, then gained by 17.39% to $27000.0 in 2023, then changed by 0.0% to $27000.0 in 2024, then slumped by 48.15% to $14000.0 in 2025.
- Business Quant data shows CGTX's Depreciation & Amortization (CF) at $14000.0 in Q4 2025, $15000.0 in Q3 2025, and $27000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14,000.00 |
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 26,000.00 |
| Jun 30, 2024 | 26,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Sep 30, 2023 | 25,000.00 |
| Sep 30, 2023 | 25,000.00 |
| Jun 30, 2023 | 23,000.00 |
| Jun 30, 2023 | 23,000.00 |
| Mar 31, 2023 | 21,000.00 |
| Mar 31, 2023 | 21,000.00 |